Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

INEBILIZUMAB-CDON: 355 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
355
Total FAERS Reports
21 (5.9%)
Deaths Reported
87
Hospitalizations
355
As Primary/Secondary Suspect
5
Life-Threatening
4
Disabilities
Prescription
Status

FDA Application: 761142 ·

First Report: 20180101 · Latest Report: 20250825

What Are the Most Common INEBILIZUMAB-CDON Side Effects?

#1 Most Reported
Neuromyelitis optica spectrum disorder
42 reports (11.8%)
#2 Most Reported
Headache
29 reports (8.2%)
#3 Most Reported
Pain
21 reports (5.9%)

All INEBILIZUMAB-CDON Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Neuromyelitis optica spectrum disorder 42 11.8% 1 23
Headache 29 8.2% 1 5
Covid-19 21 5.9% 2 11
Pain 21 5.9% 0 6
Nausea 20 5.6% 0 3
Pneumonia 20 5.6% 0 15
Arthralgia 18 5.1% 0 4
Fatigue 17 4.8% 1 3
Urinary tract infection 17 4.8% 2 7
Product storage error 14 3.9% 0 0
Hypoaesthesia 13 3.7% 0 4
Off label use 13 3.7% 0 6
Vomiting 10 2.8% 0 3
Asthenia 9 2.5% 0 3
Back pain 9 2.5% 0 1
Infusion related reaction 9 2.5% 0 2
Muscle spasms 9 2.5% 0 1
Drug ineffective 8 2.3% 0 1
Feeling abnormal 8 2.3% 0 1
Pain in extremity 8 2.3% 0 1

Who Reports INEBILIZUMAB-CDON Side Effects? Age & Gender Data

Gender: 86.8% female, 13.2% male. Average age: 52.6 years. Most reports from: US. View detailed demographics →

Is INEBILIZUMAB-CDON Getting Safer? Reports by Year

YearReportsDeathsHosp.
2018 1 0 0
2020 14 0 1
2021 43 1 7
2022 13 2 4
2023 29 1 9
2024 61 4 24
2025 38 1 14

View full timeline →

What Is INEBILIZUMAB-CDON Used For?

IndicationReports
Neuromyelitis optica spectrum disorder 233
Product used for unknown indication 107
Immunoglobulin g4 related disease 7

INEBILIZUMAB-CDON vs Alternatives: Which Is Safer?

INEBILIZUMAB-CDON vs INEXIUM INEBILIZUMAB-CDON vs INFLIXIMAB INEBILIZUMAB-CDON vs INFLIXIMAB-ABDA INEBILIZUMAB-CDON vs INFLIXIMAB-AXXQ INEBILIZUMAB-CDON vs INFLIXIMAB-DYYB INEBILIZUMAB-CDON vs INFLIXIMAB, RECOMBINANT INEBILIZUMAB-CDON vs INFLUENZA A VIRUS A/CALIFORNIA/7/2009 LIVE ANTIGEN\INFLUENZA A VIRUS A/TEXAS/50/2012 LIVE ANTIGEN\INFLUENZA B VIRUS B/BRISBANE/60/2008 LIVE ANTIGEN\INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 LIVE ANTIGEN INEBILIZUMAB-CDON vs INFLUENZA VIRUS VACCINE INEBILIZUMAB-CDON vs INFLUENZA VIRUS VACCINE QUADRIVALENT TYPE A+B INEBILIZUMAB-CDON vs INGENOL MEBUTATE

Official FDA Label for INEBILIZUMAB-CDON

Official prescribing information from the FDA-approved drug label.